MAP2K7 and prostate carcinoma: Sensitivity of the prostate carcinoma DU145, PC3 and 22Rv1 cells to the MEK inhibitor AZD6244, the HDAC inhibitor ACY1215 and paclitaxel was assessed by growth-inhibition assays following 72 h drug exposure (Supplementary Table 1).